Abstracts tagged "autoimmune diseases"

Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Allyson Egan¹, Pasupathy Sivasothy², Lisa Willcocks², Rachel Jones², Marcos Martinez Del Pero³ and David R.W. Jayne⁴, ¹Vasculitis and Lupus Centre, Cambridge University Hospital, University of Cambridge, London, United Kingdom, ²Vasculitis and Lupus Centre, Department of Medicine, Cambridge University Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Centre, Cambridge University Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0617 • ACR Convergence 2021
Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease
Maria I. Danila, Lesley Jackson, Amy Mudano, Giovanna Rosas, Jeanne Merchant, Jeffrey Foster and Kenneth Saag, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Alabama lags behind many other states in COVID-19 vaccination uptake and racial/ethnic minority groups face COVID-19 vaccine access disparities. Moreover, lack of vaccination access…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
Abstract Number: 1459 • ACR Convergence 2021
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
Eric Morand¹, Gabriel Abreu², Richard Furie³ and Raj Tummala⁴, ¹Monash University, Melbourne, Australia, ²BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a treat-to-target (T2T) endpoint for SLE, is prospectively validated as protective from flares and damage accrual.1 LLDAS…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…
Abstract Number: 1741 • ACR Convergence 2021
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Kenneth Kalunian¹, Maria Dall'Era², Richard Furie³, Eric Morand⁴, Konstantina Psachoulia⁵, Emmanuelle Maho⁶, Catharina Lindholm⁷ and Raj Tummala⁵, ¹University of California, La Jolla, CA, ²University of California San Francisco, San Francisco, CA, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 0092 • ACR Convergence 2021
Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: While patients with systemic rheumatic diseases (SRDs) are in general more vulnerable to infections due to their underlying immune dysregulation and immunomodulatory therapies, data…
Abstract Number: 0187 • ACR Convergence 2021
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Vanessa Smith¹, Shervin Assassi², Yannick Allanore³, Lazaro Loaiza⁴, Inga Tschoepe⁵, Madhu Kanakapura⁴ and Elizabeth Volkmann⁶, ¹Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁵Elderbrook Solutions, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁶Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The efficacy and safety of nintedanib have been investigated in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial and in patients with…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
Abstract Number: 0634 • ACR Convergence 2021
Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
Andrea Healy¹, Johny Fares¹, Martin Bergman², Kaleb Michaud³, Alison Petro³ and Harlan Sayles³, ¹Main Line Health, Wynnewood, PA, ²Martin Jan Bergman, MD, Ridley Park, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There has been significant work developing questionnaires to find effective and reliable ways of characterizing the functional status of patients, to track disease progression…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1096 • ACR Convergence 2021
CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
Michael Paley¹, Brandi Baker², Steven Dunham³, Nicole Linskey³, Elisha Roberson³, David Clifford³ and Wayne Yokoyama³, ¹Washington University in St. Louis, Olivette, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Neuroinflammation is a severe manifestation of the systemic inflammatory disorders. Sarcoidosis, which leads to neurologic disease in 5-10 % of cases, has traditionally been…
Abstract Number: 1492 • ACR Convergence 2021
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
Robert Clancy¹, Miranda Marion², Hannah Ainsworth², Miao Chang¹, Timothy Howard³, Peter Izmirly⁴, Mala Masson⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Wake Forest University, Quakertown, NC, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Wake Forest University, Winston Salem, NC
Background/Purpose: Unknown factors trigger the transition of anti-Ro+ mothers of neonatal lupus (NL) children from preclinical autoimmunity to clinical disease. One candidate may be the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].